NCT02853084View on ClinicalTrials.gov

HL2351 CAPS Phase II Study

PHASE2TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

January 31, 2019

Conditions

Cryopyrin-Associated Periodic Syndromes (CAPS)

Interventions

DRUG

HL2351

The dose will be adjusted based on disease activities

Trial Locations (1)

Unknown

Handok Inc., Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Handok Inc.

INDUSTRY